Biomarkers of Drug-Induced Autophagy Disruption

Abstract

Drug-induced autophagy disruption has emerged as a critical concern in pharmacotherapy, influencing drug efficacy and contributing to adverse drug reactions. The identification and validation of reliable biomarkers for drug-induced autophagy disruption are essential for early detection, risk stratification, and personalized management of patients exposed to autophagy-modulating agents. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic modalities, treatment strategies, and recent advances in biomarkers of drug-induced autophagy disruption, with a focus on clinical applicability and guideline-based recommendations for healthcare professionals.

Introduction

Autophagy, a lysosome-mediated intracellular degradation process, is fundamental for cellular homeostasis and adaptation to metabolic stress. Pharmacological agents that inadvertently disrupt autophagic flux can precipitate a spectrum of clinical outcomes, ranging from cytoprotection failure to enhanced cellular toxicity. As the portfolio of drugs with autophagy-modulating properties expands, there is a growing need for precise biomarkers to monitor autophagic integrity in patients. Understanding drug-induced autophagy disruption and its biomarkers is imperative for optimizing therapeutic regimens and safeguarding patient safety.

Epidemiology / Disease Burden

The prevalence of drug-induced autophagy disruption is challenging to quantify due to variability in clinical presentation and diagnostic limitations. Agents including antineoplastics (e.g., doxorubicin, cisplatin), immunosuppressants (e.g., rapamycin analogues), and certain antipsychotics have been implicated in autophagy modulation. Incidence rates are higher in populations undergoing polypharmacy, oncology, and transplant medicine, where autophagy-altering drugs are frequently co-administered. The burden is further compounded by the potential for cumulative organ toxicity and drug resistance in these cohorts.

Pathophysiology

Drug-induced autophagy disruption occurs through diverse mechanisms. Some agents, like chloroquine and hydroxychloroquine, inhibit autophagosome-lysosome fusion, leading to impaired autophagic flux. Others, such as mTOR inhibitors, modulate upstream signaling pathways, affecting autophagosome formation. The resultant accumulation or depletion of autophagic substrates can trigger cellular dysfunction, apoptosis, or necrosis. These molecular events underpin the clinical consequences observed in patients, including organ-specific toxicity and altered pharmacodynamics of co-administered medications.

Risk Factors

Risk factors for drug-induced autophagy disruption encompass genetic predispositions (e.g., polymorphisms in ATG genes), advanced age, comorbid conditions (e.g., hepatic or renal impairment), concomitant use of multiple autophagy-modulating drugs, and underlying malignancies. Immunocompromised status and critical illness may further amplify susceptibility due to altered drug metabolism and increased cellular stress, highlighting the importance of individualized risk assessment in clinical practice.

Clinical Features

The clinical manifestations of autophagy disruption are heterogeneous and organ-specific. Cardiotoxicity (notably with anthracyclines), neurotoxicity, myopathy, and hepatotoxicity are among the most reported sequelae. Symptoms may range from subclinical biochemical abnormalities to overt organ failure. Notably, impaired autophagy can also modulate immune responses, increasing infection risk or precipitating autoimmune phenomena. Early recognition of these features is contingent upon awareness of at-risk patient populations and the pharmacological profiles of implicated drugs.

Diagnosis

Diagnosis of drug-induced autophagy disruption relies on a combination of clinical suspicion, laboratory biomarkers, and, where feasible, tissue analysis. Key biomarkers include the accumulation of microtubule-associated protein 1 light chain 3-II (LC3-II), p62/SQSTM1, and Beclin-1, detectable through immunoblotting of tissue or peripheral blood samples. Novel approaches using circulating microRNAs (e.g., miR-34a, miR-376b) and exosomal proteins are under investigation. Functional assays, such as autophagic flux measurement using lysosomal inhibitors, provide further diagnostic specificity but are not yet widely available in clinical practice.

Treatment & Management

Management strategies focus on early identification and withdrawal or dose adjustment of the causative agent, supportive care, and targeted interventions to restore autophagic balance. In select cases, pharmacological modulators of autophagy, such as mTOR inhibitors or lysosomal enhancers, may be considered under expert guidance. Multidisciplinary collaboration involving clinical pharmacologists, pathologists, and relevant specialists is essential for optimal management, especially in complex cases involving multiple comorbidities and polypharmacy.

Recent Advances / Emerging Therapies

Recent research has focused on high-throughput proteomic and transcriptomic profiling to identify novel circulating biomarkers of autophagy disruption. Advances in liquid biopsy technology have enabled minimally invasive monitoring of autophagic activity through cell-free nucleic acids and exosome analysis. Small-molecule modulators with selective autophagy-restoring properties are in preclinical and early-phase clinical trials, offering promise for future therapeutic interventions. Integration of biomarker-driven monitoring into electronic health records is also being piloted to facilitate real-time risk assessment.

Guideline Recommendations

Consensus guidelines emphasize pre-therapy risk stratification for patients prescribed known autophagy-modulating drugs, including baseline and serial monitoring of relevant biomarkers in high-risk cohorts. Multidisciplinary teams should be engaged for patients with abnormal biomarker profiles or clinical features suggestive of autophagy disruption. Reporting of suspected cases to pharmacovigilance systems is encouraged to enhance the epidemiological understanding and inform future guideline development. Clinicians are advised to stay updated with evolving evidence and incorporate biomarker assessment into routine practice where feasible.

Conclusion

Biomarkers of drug-induced autophagy disruption represent a rapidly evolving field with significant implications for clinical practice. Early identification and intervention can mitigate adverse outcomes and optimize therapeutic efficacy. Ongoing research into novel biomarkers and targeted therapies holds the potential to revolutionize the management of patients exposed to autophagy-modulating agents. Integration of guideline-based recommendations and multidisciplinary expertise will be pivotal in advancing patient safety and personalized medicine in this domain.